MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Level 2 - randomized trial
Individual multi-site randomized, double-blind, placebo-controlled trial
PubMed 33972795 · doi:10.1038/s41591-021-01336-3
What was done
In a multi-site phase 3 randomized, double-blind, placebo-controlled trial (NCT03537014), 90 adults with severe post-traumatic stress disorder (PTSD)—including comorbidities such as depression, dissociation, childhood trauma, and past substance use disorders—underwent psychiatric medication washout and were randomized 1:1 to receive manualized therapy with either MDMA or inactive placebo. Treatment included three preparatory sessions, three dosing sessions, and nine integrative therapy sessions. The primary outcome was change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score from baseline to 2 months after the final experimental session; the secondary outcome was functional impairment on the Sheehan Disability Scale (SDS). Safety, suicidality, and adverse events were monitored.
What was found
MDMA-assisted therapy produced a statistically significant reduction in PTSD symptoms compared with placebo (P < 0.0001, effect size d = 0.91). Mean change in CAPS-5 scores among completers was -24.4 (s.d. 11.6) in the MDMA group versus -13.9 (s.d. 11.5) in the placebo group. Functional impairment on the SDS was also significantly improved in the MDMA arm (P = 0.0116, d = 0.43). No MDMA-induced adverse events related to abuse potential, suicidality, or QT prolongation were observed.
Why it matters
This phase 3 trial provides rigorous randomized evidence that MDMA-assisted psychotherapy can substantially reduce severe PTSD symptoms and associated disability, even in complex clinical populations with high comorbidity.
Limits
The total sample size was modest (n = 90). The primary follow-up window was limited to 2 months post-treatment, leaving long-term durability unaddressed in this report. The use of an inactive placebo creates a high risk of functional unblinding given MDMA's distinct subjective psychoactive effects. Complete psychiatric medication washout also excludes patients unable or unwilling to taper existing psychotropic medications.
Cited by
- context Clinical trials showed up to 67% PTSD remission or significant reduction from two sessions of MDMA with a qualified therapist in a clinical setting.